Where is nano today and where is it headed? A review of nanomedicine and the dilemma of nanotoxicology
C Domingues, A Santos, C Alvarez-Lorenzo… - ACS …, 2022 - ACS Publications
Worldwide nanotechnology development and application have fueled many scientific
advances, but technophilic expectations and technophobic demands must be …
advances, but technophilic expectations and technophobic demands must be …
Translating 3D printed pharmaceuticals: From hype to real-world clinical applications
Abstract Three-dimensional (3D) printing is a revolutionary technology that is disrupting
pharmaceutical development by enabling the production of personalised printlets (3D …
pharmaceutical development by enabling the production of personalised printlets (3D …
Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine
MAS Weerink, MMRF Struys, LN Hannivoort… - Clinical …, 2017 - Springer
Dexmedetomidine is an α 2-adrenoceptor agonist with sedative, anxiolytic, sympatholytic,
and analgesic-sparing effects, and minimal depression of respiratory function. It is potent …
and analgesic-sparing effects, and minimal depression of respiratory function. It is potent …
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …
tuberculosis remains out of control in several parts of the world including Africa and Asia …
Developmental changes in pharmacokinetics and pharmacodynamics
Effective drug therapy to optimally influence disease requires an understanding of a drug's
pharmacokinetic, pharmacodynamic, and pharmacogenomic interrelationships. In …
pharmacokinetic, pharmacodynamic, and pharmacogenomic interrelationships. In …
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines
EC de Baat, RL Mulder, S Armenian… - Cochrane Database …, 2022 - cochranelibrary.com
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer
receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library Skip to Content Cookies Our …
receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library Skip to Content Cookies Our …
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology
An expert review of the aetiology, assessment, and treatment of autism spectrum disorder,
and recommendations for diagnosis, management and service provision was coordinated …
and recommendations for diagnosis, management and service provision was coordinated …
Developmental pharmacokinetics in pediatric populations
H Lu, S Rosenbaum - The Journal of Pediatric …, 2014 - meridian.allenpress.com
Information on drug absorption and disposition in infants and children has increased
considerably over the past 2 decades. However, the impact of specific age-related effects on …
considerably over the past 2 decades. However, the impact of specific age-related effects on …
Management of opioid analgesic overdose
EW Boyer - New England Journal of Medicine, 2012 - Mass Medical Soc
Management of Opioid Analgesic Overdose | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …
content The New England Journal of Medicine homepage Advanced Search SEARCH …
Clinical standards for the dosing and management of TB drugs
JWC Alffenaar, SL Stocker, LD Forsman… - … of Tuberculosis and …, 2022 - ingentaconnect.com
BACKGROUND: Optimal drug dosing is important to ensure adequate response to
treatment, prevent development of drug resistance and reduce drug toxicity. The aim of …
treatment, prevent development of drug resistance and reduce drug toxicity. The aim of …